Iontophoretic Application of Acyclovir Gel to Treat Cold Sores

NCT ID: NCT00469300

Last Updated: 2008-02-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 810 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-04-30
• Study Completion Date: 2007-10-31

Brief Summary

Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the sites where the herpes virus is replicating. Iontophoresis uses electric current to enhance delivery of drugs through the skin. This trial is testing a new iontophoretic device with a new acyclovir gel to treat cold sores.

Detailed Description

This is a multicenter, placebo controlled, randomized, double blind, subject initiated study of the safety and efficacy of a single, 10-minute, topical iontophoretic application of a novel acyclovir 5% gel for the episodic treatment of recurrent herpes labialis. The design of the trial will also allow the comparison of the efficacy of a single iontophoretic treatment with acyclovir gel within 1 hour of first signs and/or symptoms of a herpetic episode to the efficacy of a single iontophoretic treatment with acyclovir gel 6 to18 hours after first signs and/or symptoms. Approximately 810 subjects will be enrolled to treat about 80 subjects in each of three treatment arms. Depending upon how the subject has been randomized into the trial, the subject will receive either: 1) an iontophoretic treatment with active gel within 1 hour of first signs/and or symptoms, followed 6-18 hours later by a second treatment with placebo gel; 2) an iontophoretic treatment with placebo gel within 1 hour of first signs/and or symptoms, followed 6-18 hours later by a second treatment with active gel; or 3) an iontophoretic treatment with placebo gel within 1 hour of first signs/and or symptoms, followed 6-18 hours later by a second treatment with placebo gel. After being enrolled and randomized into the study, subjects will be sent home with a locked kit containing the iontophoretic device with either active or placebo gel. At first signs and/or symptoms of a recurrent herpetic episode (prodromal or erythema), the lesion will be confirmed by telephone interview with the subject and, upon confirmation of the lesion, the subject will be given the combination to the locked kit and instructed to begin treatment immediately. The subject will then be instructed to return to the clinic within 6 to 18 hours of first signs and/or symptoms for a second iontophoretic treatment, appropriate to the treatment arm into which they have been randomized, and an evaluation. The subject will visit the clinic for daily follow-up evaluations for 3 to 14 days following the first treatment and will be called 2 weeks after their last clinic visit for a final safety evaluation.

Conditions

Herpes Labialis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

Iontophoretic delivery of acyclovir

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female subject 18-75 years of age

2. Female subjects must be using a medically acceptable form of birth control during the study.

3. Subject must have a history of recurrent herpes labialis and report at least 3 recurrences during the preceding 12 months.

4. Subject must provide voluntary written informed consent to participate in this study.

Exclusion Criteria

1. Subjects with a pacemaker, a history of cardiac arrhythmias or conduction abnormalities.

2. Any evidence of active malignancy or immunodeficient disease within the last 30 days. Subjects who have completed therapy and are considered unlikely to relapse or who have had surgery and do not have any evidence of disease, are eligible for the study.

3. Subject requires chronic use of immunomodifying drugs (e.g. systemic steroids) or topical steroids on or near the face; use of inhaled steroids does not exclude a subject from the study.

4. Subject requires chronic use of anti-viral medication.

5. History of allergic or adverse response to acyclovir, or any related anti-viral drug, or the gel base.

6. In females of childbearing potential, a positive urine pregnancy test at time of screening.

7. Nursing mothers.

8. Subjects with an implantable electronic device.

9. Subject has any body piercing in or around the area ordinarily affected by cold sores.

10. Subject is considered unreliable or unable to understand or follow the protocol directions or is unable to comprehend or satisfactorily assess a herpetic lesion as determined by Investigator or designee at screening.

11. Subject has abnormal skin conditions (e.g. acne, eczema, psoriasis, albinism, or chronic vesiculobullous disorders) that occur in the area ordinarily affected by cold sores or has significant facial hair in the area of the cold sore that might affect the normal course of the cold sore or might impair accurate evaluation of the cold sore lesion.

12. Subject has had an infection with HSV-1 isolates know to be resistant to acyclovir, valacyclovir, famciclovir, or ganciclovir.

13. Subject has had a herpes vaccine.

14. Subject is currently enrolled in another clinical trial involving the use of a drug and/or a device.

15. Subject has previously participated in the current study (TPI-H-221).

16. Subject requires chronic use of analgesics, pain medication or non-steroidal anti-inflammatory agents (NSAIDs).

17. Subject has a recent history of renal dysfunction or serious hepatic disease.

18. Subject has a history of alcoholism or drug abuse within the preceding 12 months.

19. Subject shares a household with another subject already enrolled in the study (TPI-H-221). If the other household member has already completed the study, then the currently enrolling subject is not excluded.

20. Subject is institutionalized.

21. Any history which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Transport Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Principal Investigators

Eric M Morrel, PhD

Role: STUDY_DIRECTOR

Transport Pharmaceuticals, Inc.

Locations

Radiant Research Birmingham

Birmingham, Alabama, United States

Radiant Research Santa Rosa

Santa Rosa, California, United States

Radiant Research St. Petersburg

Pinellas Park, Florida, United States

Radiant Research Chicago

Chicago, Illinois, United States

Radiant Research Minneapolis

Edina, Minnesota, United States

Radiant Research St. Louis

St Louis, Missouri, United States

Rochester Clinical Research, Inc.

Rochester, New York, United States

Radiant Research Cincinnati

Cincinnati, Ohio, United States

Radiant Research Akron

Mogadore, Ohio, United States

OMEGA Medical Research

Warwick, Rhode Island, United States

Radiant Research Greer

Greer, South Carolina, United States

Radiant Research Dallas North

Dallas, Texas, United States

Radiant Research San Antonio

San Antonio, Texas, United States

Countries

United States

References

Morrel EM, Spruance SL, Goldberg DI; Iontophoretic Acyclovir Cold Sore Study Group. Topical iontophoretic administration of acyclovir for the episodic treatment of herpes labialis: a randomized, double-blind, placebo-controlled, clinic-initiated trial. Clin Infect Dis. 2006 Aug 15;43(4):460-7. doi: 10.1086/505872. Epub 2006 Jul 3.

Reference Type: BACKGROUND

PMID: 16838235 (View on PubMed)

Related Links

http://www.mayoclinic.com/invoke.cfm?id=DS00358

Mayo Clinic Cold Sore Information

Other Identifiers

TPI-H-221

Identifier Type: -

Identifier Source: org_study_id